UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies

(University of North Carolina Health Care) Last month, the pharmaceutical company Vertex released results from a large phase 3 clinical trial for cystic fibrosis patients, showing that a combination of two new cystic fibrosis drugs modestly improved lung function and offered better health outcomes for some patients. Now, scientists at the University of North Carolina School of Medicine and the University of North Carolina Marsico Lung Institute have shown that one of these drugs counteracts the intended beneficial molecular effect of the other.

Source: EurekAlert! - Medicine and Health - July 23, 2014 Category: Global & Universal Source Type: news